Eli Lilly and Company (LLY)’s Foundayo Hits New Weight Loss Milestone among Menopause Ladies
Eli Lilly said on June 7 that its oral GLP-1 Foundayo (orforglipron) showed weight-loss results in women with obesity or overweight across menopause stages. In ATTAIN 1, premenopausal patients lost up to 14.4% weight and postmenopausal up to 14.1% at 72 weeks; ATTAIN-2 reported significant loss in women with type 2 diabetes.
Positive Phase 2/clinical readout for Foundayo supports the obesity franchise and could improve expectations for oral GLP-1 adoption in a new patient segment (menopause-related weight gain).
Eli Lilly reported top-line ATTAIN 1/2 trial results for oral GLP-1 Foundayo (orforglipron), showing up to ~14% weight loss at 72 weeks across menopause stages.
Near-term upside bias for LLY on trial-data optimism, with follow-through dependent on durability, safety, and subsequent regulatory/phase milestones.
Background
Foundayo (orforglipron) is described as the only oral GLP-1 that can be taken without food or water restrictions; the article highlights top-line results from ATTAIN 1 and ATTAIN-2 in women across menopause stages.
Why it matters
If the efficacy and tolerability profile holds up in later readouts, Foundayo could strengthen Lilly’s obesity pipeline and support incremental demand from patients who prefer oral dosing or have adherence barriers with injectables.
Market relevance
New clinical efficacy datapoints for an oral GLP-1 in menopause-related obesity can shift expectations for Lilly’s obesity franchise and oral GLP-1 competitive positioning.
Market effects
Reinforces competitive momentum in oral GLP-1 development and expands the obesity market narrative into menopause-specific weight management.
No explicit regional impact stated; likely global sentiment for large-cap pharma/obesity peers.
Oral GLP-1 differentiation could influence global competitive expectations for obesity therapeutics.
Alternative perspectives
Weight-loss efficacy in a specific subgroup (menopause) may not translate into broad commercial uptake without clear safety/tolerability and long-term outcomes.
The article lacks safety/adverse-event detail, durability beyond 72 weeks, and regulatory pathway timing—key drivers for whether the market reprices LLY meaningfully.
Key entities
- companyEli Lilly and Company
Sponsor of Foundayo (orforglipron) and reporter of ATTAIN 1/2 top-line weight-loss results.
- drugFoundayo (orforglipron)
Oral GLP-1 candidate highlighted for weight loss across menopause stages.
- clinical trialATTAIN 1 / ATTAIN-2
Trials cited for premenopausal and postmenopausal efficacy outcomes, including patients with type 2 diabetes.
